Skip to main content
SpringerLink
Log in

Understanding the Value of Information from Pediatric Clinical Research

  • Commentary
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Whicher DM, Chalkidou K, Dhalla IA, et al. Comparative effectiveness research in Ontario, Canada: producing relevant and timely information for health care decision makers. Milbank Q 2009; 87 (3): 585–606.

    Article  PubMed  Google Scholar 

  2. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005; 164 (9): 552–8.

    Article  PubMed  Google Scholar 

  3. Horen B, Montastruc J-L, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002; 54 (6): 665–70.

    Article  PubMed  Google Scholar 

  4. Vernon JA, Shortenhaus SH, Mayer MH, et al. Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislation. Pediatr Drugs 2012; 14 (5): 283–94.

    Google Scholar 

  5. Willan AR. The use of value of information methods in the design and evaluation of clinical trials. In: Ungar WJ, editor. Economic evaluation in child health. Oxford: Oxford University Press, 2010: 91–110

    Google Scholar 

  6. Meyappan JD, Lampl M, Hsu LL. Parents’ assessment of risk in sickle cell disease treatment with hydroxyurea. J Pediatr Hematol Oncol 2005; 27 (12): 644–50.

    Article  PubMed  Google Scholar 

  7. Caplan A. Vaccination: facts alone do not policy make. Health Aff 2011; 30 (6): 1205–8.

    Article  Google Scholar 

  8. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338 (16): 1128–37.

    Article  PubMed  CAS  Google Scholar 

  9. Walker S, Sculpher M, Claxton K, et al. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health 2012; 15 (3): 570–9.

    Article  PubMed  Google Scholar 

  10. Bonati M, Pandolfini C, on behalf of the DEC-net Collaborative Group. Pediatric clinical trials registry. CMAJ 2005; 172 (9): 1159–60.

    PubMed  Google Scholar 

  11. Weber EH, Timmermans ITF, Offringa M. The Dutch Medicines for Children Research Network: a new resource for clinical trials. Paediatr Drugs 2009; 11 (3): 161–3.

    Article  PubMed  Google Scholar 

  12. Lehmann B. Regulation (EC) No 1901/2006 on medicinal products for paediatric use & clinical research in vulnerable populations. Child Adolesc Psychiatry Ment Health 2008; 2 (1): 37.

    Article  PubMed  Google Scholar 

  13. Napoleone E. Excellence in family paediatricians: the FIMP-MCRN (Medicines for Children Research Network) becomes a member of ENPR-EMA (European Network of Paediatric Research at the European Medicines Agency). Ital J Pediatr 2011; 37: 7.

    Article  PubMed  Google Scholar 

  14. Abrahamyan L, Li CS, Beyene J, et al. Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trials. J Clin Epidemiol 2011; 64 (3): 286–92.

    Article  PubMed  Google Scholar 

  15. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005 Mar 23; 293 (12): 1485–9.

    Article  PubMed  CAS  Google Scholar 

  16. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86 (5): 749–64.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author’s research is supported in part by an operating grant from The Ontario Ministry of Health and Long-term Care Drug Innovation Fund and kind support from The Hospital for Sick Children. The Hospital for Sick Children Centre for Genetic Medicine is providing research funding to the author. The views expressed are solely those of the author and not The Hospital for Sick Children or the Ontario Ministry of Health and Long-term Care. Neither The Hospital for Sick Children nor the Ontario Ministry of Health and Long-term Care had any role in data collection, interpretation, report writing or the decision to submit the paper for publication. The author’s work is independent of the funders.

Author information

Authors and Affiliations

  1. Child Health Evaluative Sciences, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada

    Wendy J. Ungar

  2. Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada

    Wendy J. Ungar

Authors
  1. Wendy J. Ungar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wendy J. Ungar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ungar, W.J. Understanding the Value of Information from Pediatric Clinical Research. Pediatr Drugs 14, 295–297 (2012). https://doi.org/10.1007/BF03262235

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262235

Keywords

Search

Navigation